Neuromuscular blocking


Published on

Published in: Health & Medicine
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide
  • As principais substâncias que promovem o bloqueio pós-juncional por competição são os alcalóides do curare, provenientes de plantas do gênero Chondrodendron e Strychnos. Esses compostos apresentam grande valor histórico, pois o curare são e foram compostos utilizados pelos índios para a captura de suas prezas, sendo extraídos dessas plantas e utilizados nas pontas de flechas. Como apresentavam ação paralizante da presa, o interesse por cientistas da época foi grande. E
  • A margem de segurança da transmissão neuromuscular nos permite avaliar o quanto a transmissão neuromuscular esta comprometida, no gráfico acima temos nas ordenadas a força de contração do músculo, sendo todas relativas ao registro inicial; nas abscissas encontra-se a fração de receptores bloqueados. Logo quanto maior a concentração do bloqueador competitivo, maior será a fração de receptores bloqueados, até chegar a um ponto em que a transmissão neuromuscular começa a ficar compromotida, no exemplo acima temos vários tipos de preparações e pode-se notar que a partir de 75% de bloqueio a preparações começam a apresentar o comprometimento da transmissão. Isso é muito importante no processo cirúrgico, pois o paciente pode apresentar certo grau de bloqueio mesmo sem apresentar comprometimento da transmissão, consequentemente uma dose adicional inadequada pode promover sérios efeitos (como bloqueio prolongado).
  • Temos também o outro grupo de bloquedores neuromusculares, que são os bloqueadores despolarizantes. Esses foram descobertos por Burns e Paton em 1951, sendo o primeiro o Decametônio; esses compostos apresentam estrutura semelhante a acetilcolina e apresentam uma ação de agonista estável, ou seja são capazes de interagir com o receptor (pois apresentam afinidade), no entanto, possuem pouca atividade.
  • Five years ago, a letter from Burroughs Wellcome containing this statement was sent to all anesthesiologists in Canada and the US. This was followed by a deluge of protest, so great that the company replaced the “contraindication” with a warning of the rare possibility of inducing life-threatening hyperkalemia in infants and children with undiagnosed myopathies. No other drug used in anesthesia is associated with such a high incidence of complications yet continues to be used 54 yrs after its introduction. The second is an anonymous quote but heard quite often
  • Complications assoc with Succ which present or persist into the PACU: Muscle pains Myoglobinaemia Myoglobinuria Hyperkalemia Phase II block Reduced pChE Malignant hyperthermia Anaphylaxis Often asked question: What are the contraindications to succinylcholine?
  • Vulnerable periods for Sux induced hyperkalemia: Spinal cord injuries: 24hrs to 6 months Burns:7days to 1 year
  • mechanism: reversible damage to muscle fibers caused by shearing stresses from the uncoordinated activation of individual muscle fibers is one possible explanation many suggestions to reduce or prevent fasciculations, myalgias and muscle damage: Pretreat with an NDMR, a “taming dose of Succ,benzodiazepine, lidocaine,fentanyl, MgSo4, dantrolene, Vitamin C, and Ca gluconate. Defasciculation. is probably the most reliable.-but watch out for the sensitive patient! One recent doubled blinded, randomised control study showed no difference in the incidence of myalgias comparing sux (after defasciculation with dTC) and mivacurium.
  • We would expect a blocking agent to possess a positive charge with an affinity for the complementary negative charge on the Ach receptor. It is a fact that all clinically useful NM blocking agents bear a positively charged N. At least one quaternary N is necessary to achieve high potency, by confirming the drug within a very restrictive volume of distribution An increase in the size of the N substituents leads to a decrease in depolarizing activity and generally some decrease in potency.
  • Mivacurium: Advantages: 1) short cases,2) facility with infusion Disadvantages: 1) slow onset ( can be shortened with priming) 2) hypotension with large doses, or when given quickly (less than 30 sec), 3) prolonged duration in susceptible population.
  • It still has landanosine as one of its bi-products of spontaneous degradation but because it is more potent
  • This is a series of aminosteriods with different potencies. Agents with low potencies <100 ug/kg have feaster onsets. The asymtope is at approx 90-100 sec. So even with less potent agents we may not do any better than 90-100 sec
  • Onset of NM block can be increased by administering a larger dose. The typical intubating dose is about 2.5 -3 X the ED 95 of that particular agent. By using an even larger dose onset time can be further reduced but this has an expense and that is a longer duration of action.
  • In renal failure patients, the elimination kinetics were slightly decreased for Rocuronium
  • Edrophonium and neostigmine are both Quaternary Ammonium cpds\\ Edrophonium: Predominant site of action is presynaptic. Does have mild muscarinic effects. Because of its short duration of action in small doses (e.g. 1 mg) useful in Dx of Myasthenia Crisis vs Cholinergic crisis.Dosing requirements same for children and adults but higher doses needed for elderly Neostigmine: Predominant effect is post-synaptic. Renal clearance is 50% Hepatic clearance 50%, Inactive metabolites. Time course of onset and duration produced by an equipotent does of neostigmine similar in adults and children but dose is less for children
  • It is going to be difficult to reverse a block induced with Doxacurium in “cold”and hypokalemic 80 year old on an aminoglycoside with barely one twitch with O.3 mg/kg of Edrophonium Factors prolonging NMB: Deficiency or atypical pseudocholinesterase, Hypermagnesemia,Hypothermia,Respiratory acidosis, Hypokalemia, Antibiotics
  • POST OPERATIVE RESIDUAL CURIZATION OR PARALYSIS Is a common problem especially with long acting agents Until recently the standard was TOF > 0.7 . This value was derived from “awake unanesthetized volunteers who had sign. decreases in measured FVC and max inspiratory pressures. It now appears that a TOF of >0.9 is needed to assure complete recovery from NMB, since we now know that even small degrees of block may modify respiratory response to hypoxia and predispose to aspiration!
  • Erickson in 1993 showed decreased hypoxic drive in subjects given vecuronium to reduce the TOF to <0.7 but had a normal response when TOF > 0.9 Again Erickson in 1997 demonstrated in volunteers impaired swallowing and aspiration with TOF as high as0.9
  • Sensitive to variations in current,temperature and tension preload Cannot distinguish between non-depolarizing and depolarizing block Presence of full twitch does not guarantee full recovery
  • 100 Hz not physiological
  • Four supramaximal stimuli given every 0.5 sec May be repeated to more than every 10-12 sec Each stimuli after the first causes contraction, with fade giving basis for evaluation Provides useful correlation of fade and clinical NM block. Fade can be visualized, felt or measured. But it is difficult to assess fade visually or by tactile means. Cannot monitor deep NM block
  • In non-paralyzed muscle, response is two short contractions of equal strength. In partly paralyzed muscle the second response is weaker
  • Potentiation of facilitation of contractions is seen after tetanic simulation when muscle relaxants are onboard. There is more Ach competing for receptor sites with the neuromuscular blocker. This is seen with NDMR’s but can also be observed in Phase II block induced with succinylcholine. Magnitude is a function of the depth of block.
  • Neuromuscular blocking

    1. 1. NEUROMUSCULAR BLOCKING AGENTS Carlos Darcy Alves Bersot TSA.SBA MD RESPONSÁVEL PELO CET H.F.LAGOAMédico Anestesiologista do Hospital Federal da Lagoa-SUSMédico Anestesiologista do Hospital Pedro Ernesto-UERJ
    2. 2. Key Concepts•Muscle relaxation does not ensure unconsciousness, amnesia, or analgesia•Neuromuscular blocking agents are used to improve conditions for tracheal intubation, to provideimmobility during surgery, and to facilitate mechanical ventilation.•Depolarizing muscle relaxants act as acetylcholine (ACh) receptor agonists, whereasnondepolarizing muscle relaxants function as competitive antagonists.•Depolarizing muscle relaxants are not metabolized by acetylcholinesterase, they diffuse awayfrom the neuromuscular junction and are hydrolyzed in the plasma and liver by another enzyme,pseudocholinesterase (nonspecific cholinesterase, plasma cholinesterase, orbutyrylcholinesterase).•With the exception of mivacurium, nondepolarizing agents are not significantly metabolized byeither acetylcholinesterase or pseudocholinesterase. Reversal of their blockade depends onredistribution, gradual metabolism, and excretion of the relaxant by the body, or administration ofspecific reversal agents (eg, cholinesterase inhibitors) that inhibit acetylcholinesterase enzymeactivity.•Compared with patients with low enzyme levels or heterozygous atypical enzyme in whomblockade duration is doubled or tripled, patients with homozygous atypical enzyme will have avery long blockade (eg, 4–6 h) following succinylcholine administration.•Succinylcholine is considered contraindicated in the routine management of children andadolescents because of the risk of hyperkalemia, rhabdomyolysis, and cardiac arrest in children withundiagnosed myopathies
    3. 3. •Normal muscle releases enough potassium during succinylcholine-induced depolarization to raiseserum potassium by 0.5 mEq/L. Although this is usually insignificant in patients with normal baselinepotassium levels, a life-threatening potassium elevation is possible in patients with burn injury,massive trauma, neurological disorders, and several other conditions•Doxacurium, pancuronium, vecuronium, and pipecuronium are partially excreted by the kidneys, andtheir action is prolonged in patients with renal failure.•Atracurium and cisatracurium undergo degradation in plasma at physiological pH and temperatureby organ-independent Hofmann elimination. The resulting metabolites (a monoquaternary acrylateand laudanosine) have no intrinsic neuromuscular blocking effects•Hypertension and tachycardia may occur in patients given pancuronium. These cardiovasculareffects are caused by the combination of vagal blockade and catecholamine release from adrenergicnerve endings•Long-term administration of vecuronium to patients in intensive care units has resulted in prolongedneuromuscular blockade (up to several days), possibly from accumulation of its active 3-hydroxymetabolite, changing drug clearance, or the development of a polyneuropathy•Rocuronium (0.9–1.2 mg/kg) has an onset of action that approaches succinylcholine (60–90 s),making it a suitable alternative for rapid-sequence inductions, but at the cost of a much longerduration of action.
    4. 4. History of neuromuscular blocking agents• Early 1800’s – curare • 1942 – curare used for discovered in use by muscular relaxation in South American general anesthesia Indians as arrow • 1949 – gallamine poison discovered as a• 1932 – West substitute for curare employed curare in • 1964 – more potent patients with tetanus drug pancuronium and spastic disorders synthesized
    5. 5. Bloqueadores Não-despolarizantes Curares - Chondrodendron e Strychnos Farmacologia – Texto e atlas, 4ª ed., 2003. Strychnos toxifera
    6. 6. West 1932
    7. 7. Milestones of Neuromuscular Blockade in Anesthesia• 1942 introduction of dTc in anesthesia• 1949 Succinylcholine, gallamine metocurine introduced• 1958 Monitoring of NMF with nerve stimulators• 1968 Pancuronium• 1971 introduction of TOF• 1982 Vecuronium,Pipecurium,atracurium• 1992 Mivacurium• 1994 Rocuronium• 1996 Cisatracurium• 2000 Rapacurium introduced and removed
    8. 8. Aspectos Morfológicos e Funcionais
    9. 9. Aspectos Morfológicos e Funcionais Imagem da junção Sinapse neuromuscular imagem em microscopia eletrônica neuromuscular em varredura
    10. 10. Canais Voltagem Dependentes
    11. 11. α 2βγδ (embrionário)α 2βεδ (maduro) Only the two identical α subunits are capable of binding ACh molecules
    12. 12. Neuromuscular PhysiologyAcetylcholine receptor channels Extrajunctional Junctional Anesthesia 5th ed p 740
    13. 13. Bloqueadores Não-despolarizante MECANISMO DE AÇÃO Tubocurarine Potenciais de ação e potenciais de placa terminal na vigência de bloqueador não-despolarizante
    14. 14. Bloqueadores Não-despolarizante Margem de Segurança da Transmissão Neuromuscular
    15. 15. Site of Action of d-Tubocurarine Nerve AP Muscle AP Left Leg Muscle Stimulation Right Leg Nerve StimulationRight Leg Muscle Stimulation
    16. 16. Non-depolarizing BlockBersot,CDA UFRJ
    17. 17. Bloqueadores Despolarizantes succinilcolina
    18. 18. Bersot,cda ufrj 2002
    19. 19. Farmacologia da Junção NeuromuscularBloqueadores Não-despolarizantes COMPOSTOS SINTÉTICOS Derivados Isoquinolínicos Lee, (2003) Pharmacology & Therapeutics, 98:143-169
    20. 20. Farmacologia da Junção NeuromuscularBloqueadores Não-despolarizantes COMPOSTOS SINTÉTICOS Derivados Aminoesteróides Lee, (2003) Pharmacology & Therapeutics, 98:143-169
    21. 21. Farmacologia da Junção NeuromuscularBloqueadores DespolarizantesPaton & Zaimis, 1949 – Decametônio e Succinilcolina Lee, (2003) Pharmacology & Therapeutics, 98:143-169
    22. 22. Succinylcholine“Except when used for emergency tracheal intubation or in instances in clinical practice where immediate securing of the airway is necessary, succinylcholine is contraindicated in children and adolescent patients.”
    23. 23. SuccinylcholineAdvantages DisadvantagesRapid onset Hyperkalemia (burns,massive trauma,denervation.…)Short DurationI.M. injection Cardiac Dysrhythmias Masseter Spasm Malignant Hyperthermia Myalgias Prolonged effect
    24. 24. Succinylcholine: Hyperkalemic ResponseMajor burns, Massive trauma, Denervation injuriesprolonged immobility, sepsis. – normal response; approx. 0.5 mEq/L – not attenuated by defasciculation – increased extrajunctional receptors (few days to form)
    25. 25. Succinylcholine: Myalgias• mechanism-speculative• incidence: 0.2-89%• young, female, early ambulation• severity not related to intensity of fasciculations• Pre-treatment with NDMR prevents fasciculations and may decrease myalgias
    26. 26. Succinylcholine:increased intragastric pressure – G-E junction opens at pressures > 28cm H20 – transient increase up to 40 cm H20 – Defasciculate, abolishes the rise
    27. 27. Succinylcholine: intraocular pressure – Prevention: defasciculate, benzodiazepam, lidocaine,acetazolamide, deep anesth. at laryngoscopy – Drug of Choice? for the “Glaucoma” and “full stomach” – Recommendations: SUX if possible, priorize, Airway first. – If SUX is used: sedate and defasciculate – transient increase of 8mm Hg ; peaks at 2-4 min – due to contraction of extra-ocular muscles• See Vachon C. Succinylcholine and the open globe: Tracing the Teaching Anesthesiol 99: 220-223, 2003
    28. 28. Succinylcholine:Prolonged Apnea after…. • Etiology • Diagnosis • Management
    29. 29. Prolonged Apnea after Succinylcholine Etiology • Decreased Plasma Cholinesterase Activity – Physiologic Variation – Disease States – Iatrogenic – Genetic
    30. 30. Duration of Sux induced NM-block VS pChE activity Anesthesia 5th ed p 420
    31. 31. Plasma Cholinesterase (Prolonged Apnea after….)• Disease States – Hepatic Cirrhosis (reduced 50%) – renal disease (50%), returns to normal after renal transplant – malignancy (bronchogenic, GI) – Burns
    32. 32. Plasma Cholinesterase (Prolonged Apnea after…)• Iatrogenic – echthiophate – anticholinesterases – pancuronium – pheneizine (MAO inhibitor) – glucocorticoids (estrogens) – organophosphates (insecticides) – cytotoxic drugs (cyclophosphamide)
    33. 33. Malignant Hyperthermia (Hyperpyrexia)• Condition caused by a defect in the molecule linking muscle membrane t-tubules to the sarcoplasmic reticulum (ryanodine receptor).• Uncontrolled Ca++ release from the S.R. leads to contracture and a rise in body core temperature.• Succinylcholine can precipitate an attack even in the absence of halothane like anesthetics.• Dantrolene blocks this inappropriate response of the ryanodine receptor and prevents Ca++ loss
    34. 34. Muscle Relaxants: Physio-chemical PropertiesHighly Ionized at Physiol. pH – + charged quaternary N attracted to - charged cholinergic receptor – most contain 2 + charges (biquaternary) separated by varying sizes of lipophilic bridge (potency) – quaternary ammonium (like Ach)
    35. 35. Muscle Relaxants: Physio-chemical PropertiesHighly Water Soluble/ Relatively Hydrophilic – easily excreted in urine – do not cross lipid membranes (most cells, BBB, placenta) – small volume of distribution – not actively metabolized by the liver (cytochrome P-450 enzyme system requires lipophilic substrates)
    36. 36. Pancuronium• Bis-quaternary Aminosteroid• High potency therefore slow onset• Long acting• No or slight increase on blood pressure• Vagolytic• Renal clearance
    37. 37. RocuroniumMono-quaternary aminosteroid – potency, approx 1/6 that of Vecuronium – fast onset (< I min with 0.8 mg/kg) – intermediate duration (44 min with 0.8 mg/kg) – minimal CV side effects – onset and duration prolonged in elderly – slight decrease in elimination in RF
    38. 38. MivacuriumBisquaternary benzylisoquinoline – potency, 1/3 that of atracurium – relatively slow onset 1.5 min with 0.25 mg/kg – short duration 12-18 min with 0.25 mg/kg – histamine release with doses 3-4X ED95 – hydrolyzed by pChE, recovery may be prolonged in some populations (e.g. atypical pChE)
    39. 39. Cis-Atracuriumone of the stereo isomers of atracurium (15%) – 3 X more potent than atracurium – slow onset, intermediate duration – eliminated by Hoffman degradation – Laudanosine as a metabolite – non-organ elimination – doses of 5 X ED95 (0.05mg/kg) • no histamine release • CV stability
    40. 40. Rapacuroniummonoquaternary aminosteroid, analogue of Vecuronium – low potency, fast onset, short to intermediate duration – 1.5-2.0 mg/kg doses give good intubating conditions at 60 sec – duration of action, dependent on dosage and age of patient – 20 % decrease in aBP observed with 2-3 mg/kg doses – principle route of elimination may be liver as 22% is renal excretion. – introduced in 2000 in US and removed, after paediatric deaths (bronchospasm).
    41. 41. Hemodynamic Effects of d-Tubocurarine and Pancuronium HR CO SVR MAP
    42. 42. Effect of Potency on Onset of NMB
    43. 43. Effect of Dose on Onset of NMB
    44. 44. Hepato-Biliary DiseasePancuronium (20% metabolized to active metabolite) increased Vd decreased plasma clearance prolonged elimination T1/2A large initial dose is required to prod the same plasma conc. but the block will be prolongedVecuronium (20-30%metabolized to active metabolite) initial studies yielded similar results to pancuronium later studies show effect only with large dosesRocuronium is excreted unchanged in the urine and bile. Biliary excretion (2/3) appears to the predominant route. In cirrhotic patients, rocuronium pharmacodynamics and elimination kinetics are not changed much. The prolonged onset and slightly prolonged recovery is explained by the larger Vd in these patients.
    45. 45. Percent of Dose Dependant on Renal Elimination> 90% 60-90% 40-60% <25%Gallamine (97) Pancuronium (80) d-TC (45) Succinylcholine Pipecuronium (70) Vecuronium (20) Doxacurium (70) Atracurium (NS) Metocurine (60) Mivacurium (NS) Rocuronium
    46. 46. Rationale Choice of Muscle Relaxant: Cardiovascular Effects Tachycardia Bradycardia Hypotension Arrhythmias
    47. 47. Reversal of Neuromuscular BlockadeHow?• Anticholinesterases: – Edrophonium – Neostigmine• Cholinesterase• Removal of blocking agents – Org 25969 (Cylcodextrin) • Ring of sugars that soak up Rocuronium •
    48. 48. AnticholinesterasesUnwanted side effects – Autonomic – Nausea and vomiting • Neostigmine > Edrophonium ?• Edrophonium (0.5-1.0 mg/kg) with Atropine ( 7-15 ug/kg)• Neostigmine (40-70 ug/kg) with Glycopyrolate (0.7-1.0mg)
    49. 49. Difficulty reversing block• Right dose?• Intensity of block to be reversed?• Choice of relaxant?• Age of patient?• Acid-base and electrolyte status?• Temperature?• Other drugs?
    50. 50. Cold patients-longer durations Anesthesia 5th ed p 463
    51. 51. POSTOPERATIVE RESIDUAL CURARIZATION ( PORC)• common after NDMRs• long acting > intermediate > short acting• Assoc with respir. morbidity• not observed in children• monitoring decreases incidence
    52. 52. • Ventilatory response to hypoxia is impaired and does not return to normal until TOF > 0.9 (Ericksson et al, Anesthesiology 78: 693-699 1993)• Reduced Pharyngeal muscle coordination with TOF 0.6-.08 (Ericksson et al, Anesthesiology 87: 1035-43 1997)
    53. 53. Neuromuscular Transmission
    54. 54. Approximate Relationships of % receptor blockade, ST and TOF with NDMBTotal receptors Single twitch, T1 Train of Four, T4 T4/T1Blocked % % normal % Normal100 0 090-95 0 0 T1 lost85-90 10 0 T2 lost 20 0 T3 lost80-85 25 0 T4 lost 80-90 48-58 0.6-0.7 95 69-79 0.7-0.7575 100 75-100 0.75-1.0 100 100 0.9-1.050 100 100 1.025 100 100 1.0
    55. 55. Monitoring Neuromuscular Function• Visual/tactile assessment of evoked responses• Measurement of evoked responses • Mechanomyography • Electromyography • Accelerometry
    56. 56. Monitoring Neuromuscular Function • Mechanomyography – Gold standard
    57. 57. Monitoring Neuromuscular Function • Accelerometry
    58. 58. Monitoring Neuromuscular Function SUPRAMAXIMAL STIMULATION– 10-20% above current output required to stimulate all nerve fibers– Minimizes influence of resistance and changes in electrode conductance
    59. 59. Monitoring Neuromuscular Function• STIMULATION PATTERNS • Single Impulse or Twitch (ST) • Train of Four (TOF) • Tetanus • Double Burst Simulation (DBS) • Post Tetantic Count (PTC)
    60. 60. STIMULATION PATTERNS• SINGLE TWITCH – Onset, dependency on frequency – Recovery • Control required • May still have residual paralysis
    61. 61. STIMULATION PATTERNS• TETANUS – 50 Hz, fade with NDMR’s – 100 Hz, fade without NDMR’s – Sensitive indicator of residual block
    62. 62. SIMULATION PATTERNS • TRAIN OF FOUR (TOF) – Measures continued relaxation – Identifies phase II block – No control required – Tolerable in awake patients – measurement O.7 of o.9 or 1 ????
    63. 63. STMULATION PATTERNS• DOUBLE BURST STIMULATION – Two bursts of 50Hz stimulation, separated by 750msec – Measured fade correlates with TOF – Tactile and visual evaluation of response superior to TOF
    64. 64. STIMULATION PATTERNS• POST TETANIC COUNT – 50 Hz for 5 sec, followed in 3 sec by ST@ 1 Hz – Shouldn’t be repeated more than 6 mins – Used to monitor intense block – Predicts optimal time to reversal